Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Addex Therapeutics Ltd.ADXN · Entity 8301 | Director | September 02, 2026 | September 04, 2026 |
| OnKure Therapeutics, Inc.OKUR · Entity 6550 | Director | August 07, 2026 | August 13, 2026 |
| Q32 Bio Inc.QTTB · Entity 5594 | Director | June 12, 2026 | July 22, 2026 |
| Rainier Acquisition CorpRNAQ · Entity 527 | Director | August 26, 2026 | August 26, 2026 |
| Renovacor, Inc.CHAQ · Entity 114644 | Director | April 23, 2020 | April 27, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Addex Therapeutics Ltd.
Report date September 02, 2026 · Filed September 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 219,561 |
Ending reported balance
After 2026-09-02 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-09-02 · Disposition to issuer · Disposed 219,561 · Balance 0 F1: Represents 219,561 shares of common Stock listed on SIX Swiss Exchange acquired following the exercise of options. Of these shares, 128,238 were acquired on October 26, 2022 under the deferred strike price payment plan with an initial strike price of $0.16 per share and 91,323 were acquired on November 27, 2023 with an initial strike price of $0.053 per share. On September 2, 2026, following the implementation of the Remuneration Committee's decision, the Strike price of all units was reduced to $0.032. All the other terms of the deferred strike price payment plan remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable. The strike prices indicated in this section reflect the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026. Row 2 · 2026-09-02 · Grant · Acquired 219,561 · Balance 219,561 F1: Represents 219,561 shares of common Stock listed on SIX Swiss Exchange acquired following the exercise of options. Of these shares, 128,238 were acquired on October 26, 2022 under the deferred strike price payment plan with an initial strike price of $0.16 per share and 91,323 were acquired on November 27, 2023 with an initial strike price of $0.053 per share. On September 2, 2026, following the implementation of the Remuneration Committee's decision, the Strike price of all units was reduced to $0.032. All the other terms of the deferred strike price payment plan remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable. The strike prices indicated in this section reflect the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026. |
| Stock-option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.06 · Expires 2034-01-07 | Direct | 0 |
Reported balance
After 2026-09-02 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-09-02 · Disposition to issuer · Disposed 50,000 · Balance 0 F3: The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026. F2: On September 2, 2026, following the implementation of the Remuneration Committee's decision, the exercise price of options was repriced to $0.032. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable. |
| Stock-option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.03 · Expires 2034-01-07 | Direct | 50,000 |
Reported balance
After 2026-09-02 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-09-02 · Grant · Acquired 50,000 · Balance 50,000 F3: The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026. F2: On September 2, 2026, following the implementation of the Remuneration Committee's decision, the exercise price of options was repriced to $0.032. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents 219,561 shares of common Stock listed on SIX Swiss Exchange acquired following the exercise of options. Of these shares, 128,238 were acquired on October 26, 2022 under the deferred strike price payment plan with an initial strike price of $0.16 per share and 91,323 were acquired on November 27, 2023 with an initial strike price of $0.053 per share. On September 2, 2026, following the implementation of the Remuneration Committee's decision, the Strike price of all units was reduced to $0.032. All the other terms of the deferred strike price payment plan remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable. The strike prices indicated in this section reflect the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026.
F2: On September 2, 2026, following the implementation of the Remuneration Committee's decision, the exercise price of options was repriced to $0.032. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable.
F3: The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026.
OnKure Therapeutics, Inc.
Report date August 07, 2026 · Filed August 13, 2026 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.20 · Expires 2034-10-03 | Direct | 15,300 |
Reported balance
Holding disclosure · report date 2026-08-07 · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · Balance 15,300 F1: The original Form 4, filed August 11, 2026, reported the disposition on August 7, 2026 of an option to purchase 15,300 shares of Class A Common Stock (the "Disposition"), and a corresponding acquisition of an option to purchase 15,300 shares of Class A Common Stock (the "Acquisition"), each in connection with an Option Repricing, as defined in footnote 3 of the original Form 4. The Disposition and Acquisition did not occur. F2: 1/36th of the shares subject to the option vested on November 4, 2024 and 1/36th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The original Form 4, filed August 11, 2026, reported the disposition on August 7, 2026 of an option to purchase 15,300 shares of Class A Common Stock (the "Disposition"), and a corresponding acquisition of an option to purchase 15,300 shares of Class A Common Stock (the "Acquisition"), each in connection with an Option Repricing, as defined in footnote 3 of the original Form 4. The Disposition and Acquisition did not occur.
F2: 1/36th of the shares subject to the option vested on November 4, 2024 and 1/36th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.
Q32 Bio Inc.
Report date June 12, 2026 · Filed July 22, 2026 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.64 · Expires 2036-06-11 | Direct | 10,826 |
Reported balance
After 2026-06-12 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2026-06-12 · Grant · Acquired 10,826 · Balance 10,826 F1: This Form 4 amendment is being filed solely to amend the Form 4 filed on June 16, 2026 to correct the number of options awarded to the Reporting Person on June 12, 2026. F2: The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) June 12, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 amendment is being filed solely to amend the Form 4 filed on June 16, 2026 to correct the number of options awarded to the Reporting Person on June 12, 2026.
F2: The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) June 12, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date.
Rainier Acquisition Corp
Report date August 26, 2026 · Filed August 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B ordinary sharesSEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-08-26 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: Each Class B ordinary share is convertible into one Class A ordinary share at the option of the holder, and will automatically convert at the time of the Issuer's initial business combination or earlier at the option of the holder, on a one-for-one basis. The Class B ordinary shares have no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Class B ordinary share is convertible into one Class A ordinary share at the option of the holder, and will automatically convert at the time of the Issuer's initial business combination or earlier at the option of the holder, on a one-for-one basis. The Class B ordinary shares have no expiration date.
Renovacor, Inc.
Report date April 23, 2020 · Filed April 27, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 10,000 |
Reported balance
Holding disclosure · report date 2020-04-23 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 10,000 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 02, 2026 Filed Sep 4, 2026 20:03 UTC | Addex Therapeutics Ltd. ADXN · Entity 8301 | GrantStock-option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $0.03 | $0.00 |
DisclosureSEC source: 0001104659-26-105491 · tm2624769-3_4seq1.xml · derivative · entry 4 Manke Isaac · CIK 0001622769 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2034-01-07 F3 · derivative.exercise_price: The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026. F2 · kind: On September 2, 2026, following the implementation of the Remuneration Committee's decision, the exercise price of options was repriced to $0.032. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable. Read SEC document |
| September 02, 2026 Filed Sep 4, 2026 20:03 UTC | Addex Therapeutics Ltd. ADXN · Entity 8301 | Disposition to issuerStock-option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $0.06 | $0.00 |
DisclosureSEC source: 0001104659-26-105491 · tm2624769-3_4seq1.xml · derivative · entry 3 Manke Isaac · CIK 0001622769 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2034-01-07 F3 · derivative.exercise_price: The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026. F2 · kind: On September 2, 2026, following the implementation of the Remuneration Committee's decision, the exercise price of options was repriced to $0.032. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable. Read SEC document |
| September 02, 2026 Filed Sep 4, 2026 20:03 UTC | Addex Therapeutics Ltd. ADXN · Entity 8301 | GrantCommon Stock | 219,561 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-105491 · tm2624769-3_4seq1.xml · nonDerivative · entry 2 Manke Isaac · CIK 0001622769 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 219,561 F1 · kind: Represents 219,561 shares of common Stock listed on SIX Swiss Exchange acquired following the exercise of options. Of these shares, 128,238 were acquired on October 26, 2022 under the deferred strike price payment plan with an initial strike price of $0.16 per share and 91,323 were acquired on November 27, 2023 with an initial strike price of $0.053 per share. On September 2, 2026, following the implementation of the Remuneration Committee's decision, the Strike price of all units was reduced to $0.032. All the other terms of the deferred strike price payment plan remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable. The strike prices indicated in this section reflect the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026. F1 · price: Represents 219,561 shares of common Stock listed on SIX Swiss Exchange acquired following the exercise of options. Of these shares, 128,238 were acquired on October 26, 2022 under the deferred strike price payment plan with an initial strike price of $0.16 per share and 91,323 were acquired on November 27, 2023 with an initial strike price of $0.053 per share. On September 2, 2026, following the implementation of the Remuneration Committee's decision, the Strike price of all units was reduced to $0.032. All the other terms of the deferred strike price payment plan remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable. The strike prices indicated in this section reflect the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026. Read SEC document |
| September 02, 2026 Filed Sep 4, 2026 20:03 UTC | Addex Therapeutics Ltd. ADXN · Entity 8301 | Disposition to issuerCommon Stock | 219,561 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-105491 · tm2624769-3_4seq1.xml · nonDerivative · entry 1 Manke Isaac · CIK 0001622769 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: Represents 219,561 shares of common Stock listed on SIX Swiss Exchange acquired following the exercise of options. Of these shares, 128,238 were acquired on October 26, 2022 under the deferred strike price payment plan with an initial strike price of $0.16 per share and 91,323 were acquired on November 27, 2023 with an initial strike price of $0.053 per share. On September 2, 2026, following the implementation of the Remuneration Committee's decision, the Strike price of all units was reduced to $0.032. All the other terms of the deferred strike price payment plan remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable. The strike prices indicated in this section reflect the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026. F1 · price: Represents 219,561 shares of common Stock listed on SIX Swiss Exchange acquired following the exercise of options. Of these shares, 128,238 were acquired on October 26, 2022 under the deferred strike price payment plan with an initial strike price of $0.16 per share and 91,323 were acquired on November 27, 2023 with an initial strike price of $0.053 per share. On September 2, 2026, following the implementation of the Remuneration Committee's decision, the Strike price of all units was reduced to $0.032. All the other terms of the deferred strike price payment plan remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable. The strike prices indicated in this section reflect the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026. Read SEC document |
| August 07, 2026 Filed Aug 11, 2026 20:39 UTC | OnKure Therapeutics, Inc. OKUR · Entity 6550 | GrantStock Option (right to buy) · Derivative | 15,300 | Not disclosed Strike: $4.14 | Not disclosed |
DisclosureSEC source: 0001622769-26-000002 · form4-08112026_080858.xml · derivative · entry 3 Manke Isaac · CIK 0001622769 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,300 Underlying: Class A Common Stock · 15,300 shares Expires 2034-10-03 F3 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on August 7, 2026 (the "Effective Date"). The Option Repricing applies to options with exercise prices equal to or greater than $10.00 per share held by all continuing employees and certain other service providers of the Issuer as of the Effective Date. F4 · price: Pursuant to the Option Repricing, the exercise price of the repriced options, including the reported option, has been amended to reduce the exercise price to $4.14 per share, the closing price of the Issuer's Class A Common Stock on the Effective Date. However, if an option holder exercises a repriced option before the end of a "Retention Period" through which the option holder must remain in service to the Issuer, then the option holder will be required to pay a premium exercise price that is equal to the original exercise price per share of such option. The "Retention Period" begins on the Effective Date of the Option Repricing and ends on the earliest to occur of the following: (i) February 7, 2028 or (ii) a Change in Control, as defined in the Issuer's 2021 Stock Incentive Plan or 2024 Equity Incentive Plan (as applicable). There was no change to the vesting schedules, expiration dates or number of shares underlying the repriced options. F2 · derivative.exercise_date: 1/36th of the shares subject to the option vested on November 4, 2024 and 1/36th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| August 07, 2026 Filed Aug 11, 2026 20:39 UTC | OnKure Therapeutics, Inc. OKUR · Entity 6550 | Disposition to issuerStock Option (right to buy) · Derivative | 15,300 | Not disclosed Strike: $18.20 | Not disclosed |
DisclosureSEC source: 0001622769-26-000002 · form4-08112026_080858.xml · derivative · entry 2 Manke Isaac · CIK 0001622769 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 15,300 shares Expires 2034-10-03 F3 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on August 7, 2026 (the "Effective Date"). The Option Repricing applies to options with exercise prices equal to or greater than $10.00 per share held by all continuing employees and certain other service providers of the Issuer as of the Effective Date. F4 · price: Pursuant to the Option Repricing, the exercise price of the repriced options, including the reported option, has been amended to reduce the exercise price to $4.14 per share, the closing price of the Issuer's Class A Common Stock on the Effective Date. However, if an option holder exercises a repriced option before the end of a "Retention Period" through which the option holder must remain in service to the Issuer, then the option holder will be required to pay a premium exercise price that is equal to the original exercise price per share of such option. The "Retention Period" begins on the Effective Date of the Option Repricing and ends on the earliest to occur of the following: (i) February 7, 2028 or (ii) a Change in Control, as defined in the Issuer's 2021 Stock Incentive Plan or 2024 Equity Incentive Plan (as applicable). There was no change to the vesting schedules, expiration dates or number of shares underlying the repriced options. F2 · derivative.exercise_date: 1/36th of the shares subject to the option vested on November 4, 2024 and 1/36th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| August 07, 2026 Filed Aug 11, 2026 20:39 UTC | OnKure Therapeutics, Inc. OKUR · Entity 6550 | GrantStock Option (right to buy) · Derivative | 300,000 | $0.00 Strike: $4.14 | $0.00 |
DisclosureSEC source: 0001622769-26-000002 · form4-08112026_080858.xml · derivative · entry 1 Manke Isaac · CIK 0001622769 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 300,000 Underlying: Class A Common Stock · 300,000 shares Expires 2036-08-06 F1 · derivative.exercise_date: 1/4th of the shares subject to the option shall vest on February 24, 2027 and 1/48th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| June 30, 2026 Filed Jul 2, 2026 20:30 UTC | Q32 Bio Inc. QTTB · Entity 5594 | Exercise / conversionStock Option (Right to Buy) · Derivative | 53,521 | $0.00 Strike: $2.80 | $0.00 |
DisclosureSEC source: 0001193125-26-294694 · ownership.xml · derivative · entry 2 Manke Isaac · CIK 0001622769 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 53,521 shares Expires 2035-10-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares underlying this option are fully vested and exercisable. Read SEC document |
| June 30, 2026 Filed Jul 2, 2026 20:30 UTC | Q32 Bio Inc. QTTB · Entity 5594 | Exercise / conversionCommon Stock | 53,521 | $2.80 | $149,858.80 |
DisclosureSEC source: 0001193125-26-294694 · ownership.xml · nonDerivative · entry 1 Manke Isaac · CIK 0001622769 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,521 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 12, 2026 Filed Jun 16, 2026 20:30 UTC | Q32 Bio Inc. QTTB · Entity 5594 | GrantStock Option (Right to Buy) · Derivative | 9,810 | $0.00 Strike: $12.64 | $0.00 |
DisclosureSEC source: 0001193125-26-272698 · ownership.xml · derivative · entry 1 Manke Isaac · CIK 0001622769 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,810 Underlying: Common Stock · 9,810 shares Expires 2036-06-11 F1 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) June 12, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| June 12, 2026 Filed Jul 22, 2026 00:25 UTC Amendment | Q32 Bio Inc. QTTB · Entity 5594 | GrantStock Option (Right to Buy) · Derivative | 10,826 | $0.00 Strike: $12.64 | $0.00 |
DisclosureSEC source: 0001193125-26-310969 · ownership.xml · derivative · entry 1 Manke Isaac · CIK 0001622769 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,826 Underlying: Common Stock · 10,826 shares Expires 2036-06-11 F1 · shares: This Form 4 amendment is being filed solely to amend the Form 4 filed on June 16, 2026 to correct the number of options awarded to the Reporting Person on June 12, 2026. F2 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) June 12, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date. F1 · derivative.underlying_shares: This Form 4 amendment is being filed solely to amend the Form 4 filed on June 16, 2026 to correct the number of options awarded to the Reporting Person on June 12, 2026. F1 · balance_after: This Form 4 amendment is being filed solely to amend the Form 4 filed on June 16, 2026 to correct the number of options awarded to the Reporting Person on June 12, 2026. Read SEC document |
| December 31, 2025 Filed Jan 2, 2026 21:10 UTC | OnKure Therapeutics, Inc. OKUR · Entity 6550 | GrantClass A Common Stock | 5,258 | $0.00 | $0.00 |
DisclosureSEC source: 0001622769-26-000001 · form4-01022026_090120.xml · nonDerivative · entry 1 Manke Isaac · CIK 0001622769 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,583 F1 · shares: These securities are fully vested restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Class A Common Stock. The RSUs were granted to the Reporting Person in lieu of a quarterly cash retainer, at the election of the Reporting Person, under the Issuer's Outside Director Compensation Policy. Read SEC document |
| October 23, 2025 Filed Oct 28, 2025 01:26 UTC | Q32 Bio Inc. QTTB · Entity 5594 | GrantStock Option (Right to Buy) · Derivative | 53,521 | $0.00 Strike: $2.80 | $0.00 |
DisclosureSEC source: 0001193125-25-251993 · ownership.xml · derivative · entry 1 Manke Isaac · CIK 0001622769 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,521 Underlying: Common Stock · 53,521 shares Expires 2035-10-22 F1 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) October 23, 2026 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| September 30, 2025 Filed Oct 2, 2025 20:16 UTC | OnKure Therapeutics, Inc. OKUR · Entity 6550 | GrantClass A Common Stock | 5,545 | $0.00 | $0.00 |
DisclosureSEC source: 0001622769-25-000003 · form4-10022025_081020.xml · nonDerivative · entry 1 Manke Isaac · CIK 0001622769 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,325 F1 · shares: These securities are fully vested restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Class A Common Stock. The RSUs were granted to the Reporting Person in lieu of a quarterly cash retainer, at the election of the Reporting Person, under the Issuer's Outside Director Compensation Policy. Read SEC document |
| June 30, 2025 Filed Jul 2, 2025 20:26 UTC | OnKure Therapeutics, Inc. OKUR · Entity 6550 | GrantClass A Common Stock | 6,311 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-019052 · form4-07022025_080710.xml · nonDerivative · entry 1 Manke Isaac · CIK 0001622769 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,780 F1 · shares: These securities are fully vested restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Class A Common Stock. The RSUs were granted to the Reporting Person in lieu of a quarterly cash retainer, at the election of the Reporting Person, under the Issuer's Outside Director Compensation Policy. Read SEC document |
| May 28, 2025 Filed May 30, 2025 20:53 UTC | OnKure Therapeutics, Inc. OKUR · Entity 6550 | GrantStock Option (right to buy) · Derivative | 7,650 | $0.00 Strike: $2.44 | $0.00 |
DisclosureSEC source: 0001415889-25-015018 · form4-05302025_080518.xml · derivative · entry 1 Manke Isaac · CIK 0001622769 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,650 Underlying: Class A Common Stock · 7,650 shares Expires 2035-05-27 F1 · derivative.exercise_date: 100% of the shares subject to the option will vest on the earlier of May 28, 2026 or the day prior to the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through the applicable vesting date. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 20:37 UTC | OnKure Therapeutics, Inc. OKUR · Entity 6550 | GrantClass A Common Stock | 3,469 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-009659 · form4-04022025_080441.xml · nonDerivative · entry 1 Manke Isaac · CIK 0001622769 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,469 F1 · shares: These securities are fully vested restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Class A Common Stock. The RSUs were granted to the Reporting Person in lieu of a quarterly cash retainer, at the election of the Reporting Person, under the Issuer's Outside Director Compensation Policy. Read SEC document |
| February 24, 2025 Filed Feb 27, 2025 11:05 UTC | Q32 Bio Inc. QTTB · Entity 5594 | GrantStock Option (Right to Buy) · Derivative | 19,008 | $0.00 Strike: $2.53 | $0.00 |
DisclosureSEC source: 0000950170-25-028306 · ownership.xml · derivative · entry 7 Manke Isaac · CIK 0001622769 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,008 Underlying: Common Stock · 19,008 shares Expires 2035-01-14 F3 · derivative.exercise_price: The exercise price of the option is $2.54 per share, representing the fair market value per share of the Issuer's Common Stock on the Repricing Date; provided that in the event (i) the option is exercised prior to the one-year anniversary of the Repricing Date, (ii) the Reporting Person's employment is terminated by the Company prior to the one-year anniversary of the Repricing Date due to Cause (as defined in the 2024 Plan) or (iii) the Reporting Person resigns for any reason prior to the one-year anniversary of the Repricing Date, the exercise price will be increased to the exercise price of the cancelled option in exchange for which this option was granted. F1 · kind: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · derivative.exercise_date: This stock option award was issued pursuant to the Q32 Bio Inc. 2017 Stock Option and Grant Plan (the "2017 Plan") or the Q32 Bio Inc. 2024 Stock Option and Incentive Plan (the "2024 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| February 24, 2025 Filed Feb 27, 2025 11:05 UTC | Q32 Bio Inc. QTTB · Entity 5594 | Disposition to issuerStock Option (Right to Buy) · Derivative | 19,008 | $0.00 Strike: $3.20 | $0.00 |
DisclosureSEC source: 0000950170-25-028306 · ownership.xml · derivative · entry 6 Manke Isaac · CIK 0001622769 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 19,008 shares Expires 2035-01-14 F1 · kind: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · derivative.exercise_date: This stock option award was issued pursuant to the Q32 Bio Inc. 2017 Stock Option and Grant Plan (the "2017 Plan") or the Q32 Bio Inc. 2024 Stock Option and Incentive Plan (the "2024 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| February 24, 2025 Filed Feb 27, 2025 11:05 UTC | Q32 Bio Inc. QTTB · Entity 5594 | GrantStock Option (Right to Buy) · Derivative | 2,627 | $0.00 Strike: $2.54 | $0.00 |
DisclosureSEC source: 0000950170-25-028306 · ownership.xml · derivative · entry 4 Manke Isaac · CIK 0001622769 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,627 Underlying: Common Stock · 2,627 shares Expires 2034-03-31 F3 · derivative.exercise_price: The exercise price of the option is $2.54 per share, representing the fair market value per share of the Issuer's Common Stock on the Repricing Date; provided that in the event (i) the option is exercised prior to the one-year anniversary of the Repricing Date, (ii) the Reporting Person's employment is terminated by the Company prior to the one-year anniversary of the Repricing Date due to Cause (as defined in the 2024 Plan) or (iii) the Reporting Person resigns for any reason prior to the one-year anniversary of the Repricing Date, the exercise price will be increased to the exercise price of the cancelled option in exchange for which this option was granted. F1 · kind: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · derivative.exercise_date: This stock option award was issued pursuant to the Q32 Bio Inc. 2017 Stock Option and Grant Plan (the "2017 Plan") or the Q32 Bio Inc. 2024 Stock Option and Incentive Plan (the "2024 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| February 24, 2025 Filed Feb 27, 2025 11:05 UTC | Q32 Bio Inc. QTTB · Entity 5594 | Disposition to issuerStock Option (Right to Buy) · Derivative | 2,627 | $0.00 Strike: $18.00 | $0.00 |
DisclosureSEC source: 0000950170-25-028306 · ownership.xml · derivative · entry 3 Manke Isaac · CIK 0001622769 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,627 shares Expires 2034-03-31 F1 · kind: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · derivative.exercise_date: This stock option award was issued pursuant to the Q32 Bio Inc. 2017 Stock Option and Grant Plan (the "2017 Plan") or the Q32 Bio Inc. 2024 Stock Option and Incentive Plan (the "2024 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| February 24, 2025 Filed Feb 27, 2025 11:05 UTC | Q32 Bio Inc. QTTB · Entity 5594 | GrantStock Option (Right to Buy) · Derivative | 12,767 | $0.00 Strike: $2.54 | $0.00 |
DisclosureSEC source: 0000950170-25-028306 · ownership.xml · derivative · entry 2 Manke Isaac · CIK 0001622769 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,767 Underlying: Common Stock · 12,767 shares Expires 2034-03-24 F3 · derivative.exercise_price: The exercise price of the option is $2.54 per share, representing the fair market value per share of the Issuer's Common Stock on the Repricing Date; provided that in the event (i) the option is exercised prior to the one-year anniversary of the Repricing Date, (ii) the Reporting Person's employment is terminated by the Company prior to the one-year anniversary of the Repricing Date due to Cause (as defined in the 2024 Plan) or (iii) the Reporting Person resigns for any reason prior to the one-year anniversary of the Repricing Date, the exercise price will be increased to the exercise price of the cancelled option in exchange for which this option was granted. F1 · kind: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · derivative.exercise_date: This stock option award was issued pursuant to the Q32 Bio Inc. 2017 Stock Option and Grant Plan (the "2017 Plan") or the Q32 Bio Inc. 2024 Stock Option and Incentive Plan (the "2024 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| February 24, 2025 Filed Feb 27, 2025 11:05 UTC | Q32 Bio Inc. QTTB · Entity 5594 | Disposition to issuerStock Option (Right to Buy) · Derivative | 12,767 | $0.00 Strike: $16.82 | $0.00 |
DisclosureSEC source: 0000950170-25-028306 · ownership.xml · derivative · entry 1 Manke Isaac · CIK 0001622769 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,767 shares Expires 2034-03-24 F1 · kind: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · derivative.exercise_date: This stock option award was issued pursuant to the Q32 Bio Inc. 2017 Stock Option and Grant Plan (the "2017 Plan") or the Q32 Bio Inc. 2024 Stock Option and Incentive Plan (the "2024 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| January 15, 2025 Filed Feb 27, 2025 11:05 UTC | Q32 Bio Inc. QTTB · Entity 5594 | GrantStock Option (Right to Buy) · Derivative | 19,008 | $0.00 Strike: $3.20 | $0.00 |
DisclosureSEC source: 0000950170-25-028306 · ownership.xml · derivative · entry 5 Manke Isaac · CIK 0001622769 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,008 Underlying: Common Stock · 19,008 shares Expires 2035-01-14 F4 · kind: This option was granted to the Reporting Person, a director of the Issuer pursuant to the 2024 Plan and pursuant to the Issuer's non-employee director compensation policy. This option represents the Reporting Person's election to receive stock options in lieu of cash retainer fees Due to administrative oversight this option award initially was not reported. F4 · derivative.exercise_date: This option was granted to the Reporting Person, a director of the Issuer pursuant to the 2024 Plan and pursuant to the Issuer's non-employee director compensation policy. This option represents the Reporting Person's election to receive stock options in lieu of cash retainer fees Due to administrative oversight this option award initially was not reported. Read SEC document |
| October 04, 2024 Filed Oct 8, 2024 23:27 UTC | OnKure Therapeutics, Inc. OKUR · Entity 6550 | GrantStock Option (right to buy) · Derivative | 15,300 | $0.00 Strike: $18.20 | $0.00 |
DisclosureSEC source: 0001415889-24-024919 · form4-10082024_111032.xml · derivative · entry 1 Manke Isaac · CIK 0001622769 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,300 Underlying: Class A Common Stock · 15,300 shares Expires 2034-10-03 F1 · derivative.exercise_date: 1/36th of the shares subject to the option shall vest on November 4, 2024 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| April 01, 2024 Filed Sep 30, 2024 10:01 UTC | Q32 Bio Inc. QTTB · Entity 5594 | GrantStock Option (Right to Buy) · Derivative | 2,627 | $13.42 Strike: $18.00 | $35,254.34 |
DisclosureSEC source: 0000950170-24-110152 · ownership.xml · derivative · entry 1 Manke Isaac · CIK 0001622769 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,627 Underlying: Common Stock · 2,627 shares Expires 2034-03-31 F1 · kind: This option was granted in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive equity in lieu of cash compensation for services as a non-employee director of the Issuer. F2 · derivative.exercise_date: The shares underlying this option vest in three equal quarterly installments on each of June 30, 2024, September 30, 2024 and December 31, 2024. Read SEC document |
| March 25, 2024 Filed Mar 27, 2024 21:42 UTC | Q32 Bio Inc. QTTB · Entity 5594 | GrantStock Option (Right to Buy) · Derivative | 12,767 | $0.00 Strike: $16.82 | $0.00 |
DisclosureSEC source: 0000950170-24-037403 · ownership.xml · derivative · entry 1 Manke Isaac · CIK 0001622769 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,767 Underlying: Common Stock · 12,767 shares Expires 2034-03-24 F1 · derivative.exercise_date: One-third of the shares underlying this option shall vest and become exercisable on March 25, 2025, with the remainder vesting in twenty-four (24) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.